Omalizumab prevents anaphylactoid reactions to mRNA COVID-19 vaccine.

Smola, A; Samadzadeh, S; Müller, L; Adams, O; Homey, B; Albrecht, P; Meller, S

Smola, A; Samadzadeh, S; Müller, L; Adams, O; Homey, B; Albrecht, P; Meller, S.

Smola A; Department of Dermatology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Samadzadeh S; Department of Neurology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Müller L; Institute of Virology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Adams O; Institute of Virology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Homey B; Department of Dermatology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Albrecht P; Department of Neurology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
Meller S; Department of Dermatology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.

J Eur Acad Dermatol Venereol ; 35(11): e743-e745, 2021 Nov.

Article in English | MEDLINE | ID: covidwho-1325019

Subject(s)

Anaphylaxis; COVID-19; Anaphylaxis/chemically induced; Anaphylaxis/prevention & control; COVID-19 Vaccines; Humans; Omalizumab/adverse effects; RNA, Messenger; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Anaphylaxis Topics: Vaccines Limits: Humans Language: English Journal: J Eur Acad Dermatol Venereol Journal subject: Dermatology / Sexually Transmitted Diseases Year: 2021 Document Type: Article Affiliation country: Jdv.17549

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google